European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.

Etripamil is a self-administered nasal spray designed to be a rapid-response therapy for episodic cardiovascular conditions. Positive topline data were announced from a phase 3 trial evaluating the ...

Etripamil is a calcium channel blocker designed to be administered intranasally to treat episodes of PSVT in an at-home setting. The Food and Drug Administration (FDA) has accepted for review the New ...

Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with ...

A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular tachycardia (PSVT), according to top-line results of ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...